2nd April 2015

Atnahs Acquires Naprosyn®, Anaprox® and Toradol®

Basildon, UK, April 2015 – Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Naprosyn®, Anaprox® and Toradol® from F.Hoffmann-La Roche Limited, effective from 31st March 2015.

Naprosyn® and Anaprox® are oral treatments for rheumatoid arthritis, osteoarthrosis (degenerative arthritis), acute gout and acute musculoskeletal disorders. Toradol® is an injectable and oral treatment for the short-term management of moderate to severe acute post-operative pain.

This is Atnahs’ third acquisition since its inception and is important in terms of its size and the number of territories that it covers.

Amit Patel, Atnahs’ Managing Director, comments “The acquisition of Naprosyn®, Anaprox® and Toradol® is extremely exciting; broadening our portfolio and building significantly on our presence overseas. Atnahs is now represented in 5 continents and 40 countries including Asia, Australasia, Canada and the US, South Africa and mainland Europe. ”

Mark Cotterill, Group CEO further comments, “Atnahs’ flexibility and ability to transact were demonstrated during this acquisition, which was completed within two months. The team are now focused on working in partnership with Roche on transitioning the products across all of the markets into our international distribution network to ensure the seamless provision of Naprosyn®, Anaprox® and Toradol®.”

About Atnahs

Atnahs is a family owned pharmaceutical business, created by the management team which established, developed and sold Amdipharm Plc to Cinven in November 2012 for £367m.

Atnahs’ Management Team is leveraging its depth of experience and heritage to create a new platform for growth. International acquisitions of niche established branded medicines coupled with a pipeline of niche generic medicines developed in our own facility form the core of our strategy.